GSK CEO Sees China’s Wider Drug Access Overcoming Price-Cap Onus
This article was originally published in PharmAsia News
GSK is betting China’s continuing healthcare reforms will increase demand for drugs enough to overcome the onus of price caps, so it plans to hire “a few hundred more” sales reps in the country.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.